Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer

This is an open-label, non-randomized, Phase I, dose escalation/dose expansion study in cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers. The Expansion Phase will begin in parallel one dose level lower than the highest dose deemed safe in the Dose Escalation in combination with a PD-1 checkpoint blockade.

Additional locations may be listed on ClinicalTrials.gov for NCT05826275.

Trial PhasePhase I

Trial Typetreatment

Lead OrganizationToragen, Inc.

• Primary IDTGN-S11
• Secondary IDsNCI-2023-04440
• ClinicalTrials.gov IDNCT05826275